Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jama M Darling

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
The American Journal of Gastroenterology|October 13, 2006
Management and treatment of hepatitis C viral infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center program and the National Hepatitis C Program office, Helen S Yee, Sue L Currie, et al.
Clinical Liver Disease|June 17, 2021
Killing Two Birds With No StoneJane Giang, Dawn S Harrison, Benjamin K Hansen, et al.
Immunology|December 4, 2002
A blood-borne antigen induces rapid T-B cell contact: a potential mechanism for tolerance inductionInes Gütgemann, Jama M Darling, Harry B Greenberg, et al.
Journal of General Internal Medicine|August 31, 2023
Inpatient Hepatitis C Treatment Coordination and Initiation for Patients Who Inject DrugsL Madeline McCrary, Kate E Roberts, Mary Catherine Bowman, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 2, 2003
Keratin 8 and 18 mutations are risk factors for developing liver disease of multiple etiologiesNam-On Ku, Jama M Darling, Sheri M Krams, et al.
Hepatology Communications|October 9, 2019
Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV-TARGET AnalysisKavita Radhakrishnan, Adrian M Di Bisceglie, K Rajender Reddy, et al.
Hepatology (Baltimore, Md.)|January 22, 2011
Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment responseJama M Darling, Jeroen Aerssens, Gregory Fanning, et al.
Gastroenterology|October 27, 2015
Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 InfectionMark S Sulkowski, Hugo E Vargas, Adrian M Di Bisceglie, et al.
Hepatology (Baltimore, Md.)|July 13, 2021
A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE StudyMark S Sulkowski, Juhi S Moon, Kenneth E Sherman, et al.
The Lancet. Infectious Diseases|March 19, 2013
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trialEric Lawitz, Jay P Lalezari, Tarek Hassanein, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
The American Journal of Gastroenterology|October 13, 2006
Management and treatment of hepatitis C viral infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center program and the National Hepatitis C Program office, Helen S Yee, Sue L Currie, et al.
Clinical Liver Disease|June 17, 2021
Killing Two Birds With No StoneJane Giang, Dawn S Harrison, Benjamin K Hansen, et al.
Immunology|December 4, 2002
A blood-borne antigen induces rapid T-B cell contact: a potential mechanism for tolerance inductionInes Gütgemann, Jama M Darling, Harry B Greenberg, et al.
Journal of General Internal Medicine|August 31, 2023
Inpatient Hepatitis C Treatment Coordination and Initiation for Patients Who Inject DrugsL Madeline McCrary, Kate E Roberts, Mary Catherine Bowman, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 2, 2003
Keratin 8 and 18 mutations are risk factors for developing liver disease of multiple etiologiesNam-On Ku, Jama M Darling, Sheri M Krams, et al.
Hepatology Communications|October 9, 2019
Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV-TARGET AnalysisKavita Radhakrishnan, Adrian M Di Bisceglie, K Rajender Reddy, et al.
Hepatology (Baltimore, Md.)|January 22, 2011
Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment responseJama M Darling, Jeroen Aerssens, Gregory Fanning, et al.
Gastroenterology|October 27, 2015
Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 InfectionMark S Sulkowski, Hugo E Vargas, Adrian M Di Bisceglie, et al.
Hepatology (Baltimore, Md.)|July 13, 2021
A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE StudyMark S Sulkowski, Juhi S Moon, Kenneth E Sherman, et al.
The Lancet. Infectious Diseases|March 19, 2013
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trialEric Lawitz, Jay P Lalezari, Tarek Hassanein, et al.
Pageof 2